Advertisement
LXEO 外汇新闻
Lexeo Therapeutics Says FDA Grants Fast Track And Orphan Drug Designation To LX2020
Genetic medicine company Lexeo Therapeutics, Inc. (LXEO) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation and Orphan Drug designation to LX2020.
RTTNews
|
596天前
